Profile data is unavailable for this security.
About the company
Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
- Revenue in EUR (TTM)529.27m
- Net income in EUR55.56m
- Incorporated1962
- Employees2.48k
- LocationVetoquinol SASainte-Anne 34 rue du CheneBp 189, Lure CedexLURE 70204FranceFRA
- Phone+33 384625555
- Fax+33 384625556
- Websitehttps://www.vetoquinol.com/fr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kissei Pharmaceutical Co Ltd | 472.74m | 73.27m | 1.05bn | 1.78k | 13.04 | 0.7039 | 10.51 | 2.23 | 268.51 | 268.51 | 1,728.18 | 4,972.53 | 0.3204 | 1.55 | 2.90 | 43,524,450.00 | 5.00 | 3.61 | 5.38 | 3.90 | 49.90 | 49.47 | 15.59 | 12.69 | 4.93 | -- | 0.006 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
| Youcare Pharmaceutical Group Co Ltd | 512.65m | 21.45m | 1.06bn | 3.18k | 49.59 | 2.29 | -- | 2.08 | 0.3757 | 0.3757 | 8.97 | 8.13 | 0.6518 | 2.07 | 4.09 | 1,269,471.00 | 2.76 | 7.11 | 4.15 | 11.65 | 59.54 | 64.14 | 4.24 | 8.07 | 1.42 | -- | 0.2079 | 60.95 | -7.61 | 1.05 | -44.84 | -7.16 | 23.40 | -- |
| Calliditas Therapeutics AB | 138.47m | -41.54m | 1.07bn | 222.00 | -- | 104.39 | -- | 7.73 | -8.95 | -8.95 | 29.83 | 1.98 | 0.9267 | 3.62 | 8.68 | 8,212,380.00 | -27.80 | -26.46 | -35.11 | -30.27 | 93.46 | -- | -30.00 | -76.59 | 2.59 | -3.07 | 0.9042 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| North China Pharmaceutical Co Ltd | 1.29bn | 6.39m | 1.08bn | 10.16k | 168.37 | 1.59 | -- | 0.8377 | 0.0293 | 0.0293 | 5.90 | 3.11 | 0.4721 | 2.78 | 4.30 | 995,956.10 | 0.4856 | -0.2978 | 1.14 | -0.7042 | 29.56 | 35.73 | 1.03 | -0.5985 | 0.5403 | 1.54 | 0.6491 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| KAKEN PHARMACEUTICAL CO., LTD. | 440.49m | 44.38m | 1.10bn | 1.14k | 20.34 | 1.04 | 17.88 | 2.49 | 192.09 | 192.09 | 1,906.84 | 3,763.43 | 0.422 | 1.98 | 3.23 | 63,566,520.00 | 4.25 | 6.83 | 4.88 | 7.87 | 53.41 | 54.78 | 10.08 | 14.48 | 3.98 | -- | 0.0263 | 51.25 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 159.85m | 15.45m | 1.10bn | 1.81k | 71.41 | 5.65 | -- | 6.90 | 0.2484 | 0.2484 | 2.57 | 3.14 | 0.4701 | 0.7661 | 1.99 | 694,836.90 | 4.96 | -2.10 | 7.42 | -3.16 | 71.43 | 69.74 | 10.56 | -6.00 | 1.16 | 12.91 | 0.1569 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
| Vetoquinol SA | 529.27m | 55.56m | 1.12bn | 2.48k | 20.02 | 2.11 | 13.82 | 2.11 | 4.70 | 4.70 | 44.73 | 44.53 | 0.7876 | 2.39 | 5.74 | 213,157.90 | 8.27 | 7.09 | 10.44 | 9.40 | 50.31 | 61.27 | 10.50 | 8.84 | 1.86 | -- | 0.0324 | 16.48 | -1.95 | 7.54 | 15.76 | 8.91 | 5.98 | 12.11 |
| ANI Pharmaceuticals Inc | 491.21m | 20.92m | 1.13bn | 642.00 | 49.78 | 2.74 | 14.62 | 2.31 | 1.19 | 1.19 | 27.93 | 22.81 | 0.6055 | 1.81 | 3.18 | 839,490.60 | 3.04 | -2.83 | 3.56 | -3.35 | 61.34 | 60.18 | 5.01 | -6.15 | 3.07 | 3.10 | 0.3725 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Ocular Therapeutix Inc | 55.68m | -126.10m | 1.14bn | 267.00 | -- | 3.29 | -- | 20.39 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| FAES Farma SA | 476.11m | 97.26m | 1.14bn | 746.00 | 11.56 | 1.64 | 9.73 | 2.39 | 0.3113 | 0.3113 | 1.52 | 2.20 | 0.5974 | 1.18 | 3.68 | 272,376.40 | 12.17 | 13.06 | 14.02 | 15.20 | 66.55 | 64.10 | 20.38 | 19.79 | 1.64 | -- | 0.0598 | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | 52.23 |
| Polypeptide Group AG | 323.22m | -51.18m | 1.15bn | 1.20k | -- | 3.02 | -- | 3.56 | -1.48 | -1.48 | 9.34 | 11.02 | 0.5137 | 2.31 | 5.08 | 257,463.10 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
Data as of Aug 15 2024. Currency figures normalised to Vetoquinol SA's reporting currency: Euro EUR
13.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 421.33k | 3.55% |
| Oddo BHF Asset Management SASas of 28 Jun 2024 | 331.47k | 2.79% |
| Invesco Advisers, Inc.as of 30 Jun 2024 | 267.01k | 2.25% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 136.11k | 1.15% |
| BNP Paribas Asset Management Europe SASas of 28 Jun 2024 | 125.40k | 1.06% |
| Cov�a Finance SASas of 28 Jun 2024 | 92.60k | 0.78% |
| Danske Bank A/S (Investment Management)as of 31 Jul 2024 | 74.79k | 0.63% |
| Amundi Asset Management SA (Investment Management)as of 28 Jun 2024 | 58.98k | 0.50% |
| Fourton Fund Management Co. Ltd.as of 31 Dec 2023 | 46.00k | 0.39% |
| Janus Henderson Investors UK Ltd.as of 31 May 2024 | 43.18k | 0.36% |
More ▼
Data from 31 Mar 2024 - 07 Aug 2024Source: FactSet Research Systems Inc.
